X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs AJANTA PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA AJANTA PHARMA ASTRAZENECA PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 86.8 21.8 398.1% View Chart
P/BV x 19.1 4.1 463.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
AJANTA PHARMA
Mar-18
ASTRAZENECA PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2781,818 70.3%   
Low Rs8831,106 79.8%   
Sales per share (Unadj.) Rs228.4239.5 95.4%  
Earnings per share (Unadj.) Rs10.452.8 19.6%  
Cash flow per share (Unadj.) Rs16.359.5 27.3%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.8230.0 43.0%  
Shares outstanding (eoy) m25.0088.77 28.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.76.1 77.5%   
Avg P/E ratio x104.227.7 376.4%  
P/CF ratio (eoy) x66.424.6 270.4%  
Price / Book Value ratio x10.96.4 172.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,008129,782 20.8%   
No. of employees `0001.46.8 20.0%   
Total wages/salary Rs m1,5353,765 40.8%   
Avg. sales/employee Rs Th4,210.93,128.4 134.6%   
Avg. wages/employee Rs Th1,132.2554.0 204.4%   
Avg. net profit/employee Rs Th191.1689.7 27.7%   
INCOME DATA
Net Sales Rs m5,71021,258 26.9%  
Other income Rs m123242 50.7%   
Total revenues Rs m5,83321,499 27.1%   
Gross profit Rs m4636,584 7.0%  
Depreciation Rs m147596 24.7%   
Interest Rs m04 0.0%   
Profit before tax Rs m4386,226 7.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1791,539 11.6%   
Profit after tax Rs m2594,686 5.5%  
Gross profit margin %8.131.0 26.2%  
Effective tax rate %40.824.7 165.2%   
Net profit margin %4.522.0 20.6%  
BALANCE SHEET DATA
Current assets Rs m3,20912,236 26.2%   
Current liabilities Rs m2,0703,461 59.8%   
Net working cap to sales %20.041.3 48.3%  
Current ratio x1.63.5 43.9%  
Inventory Days Days7260 120.1%  
Debtors Days Days3584 41.3%  
Net fixed assets Rs m79011,140 7.1%   
Share capital Rs m50177 28.3%   
"Free" reserves Rs m2,41920,237 12.0%   
Net worth Rs m2,46920,414 12.1%   
Long term debt Rs m010 0.0%   
Total assets Rs m4,60524,486 18.8%  
Interest coverage xNM1,519.4-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.9 142.8%   
Return on assets %5.619.2 29.4%  
Return on equity %10.523.0 45.7%  
Return on capital %17.730.5 58.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30011,667 2.6%   
Fx outflow Rs m2,0151,616 124.7%   
Net fx Rs m-1,71510,052 -17.1%   
CASH FLOW
From Operations Rs m882,854 3.1%  
From Investments Rs m-94-2,604 3.6%  
From Financial Activity Rs mNA-2 0.0%  
Net Cashflow Rs m-6248 -2.3%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 1.6 19.4%  
FIIs % 15.7 7.6 206.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.0 53.5%  
Shareholders   12,856 20,968 61.3%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Jet Airways and Yes Bank - What's Next for these Beaten Down Stocks?(Podcast)

Jet Airways and Yes Bank, both once market darlings are now being shunned by market participants. The National Stock Exchange (NSE) exchange notified that the shares of the airline.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

The Best 4 Small-cap Stocks to Buy(The 5 Minute Wrapup)

Jun 3, 2019

In the sometimes good sometimes bad market of small caps, there are strong buying opportunities available today. But this great opportunity won't last forever.

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Top 7 Stocks to Profit from Modi's Repeat Performance(Profit Hunter)

Jun 3, 2019

The long-term India story looks promising with the Modi government back in power. Which stocks are likely to go up the most?

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 14, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS